13
13
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2609 |
Masitinib
AB1010,马赛替尼 |
Apoptosis; FAK; c-Fms; FGFR; Bcr-Abl; PDGFR; Src; c-Kit; Hck | Angiogenesis; Apoptosis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Masitinib (AB1010) 是生物口服可利用的选择性 c-Kit 抑制剂 (对于人重组c-Kit,IC50=200 nM),它还抑制PDGFRα/β(IC50s=540/800 nM),Lyn(对 LynB 的IC50=510 nM),Lck,较小程度上抑制FGFR3和FAK。它有抗增殖,促凋亡活性,且毒性低。 | |||
T4185 |
lavendustin C
HDBA,NSC 666251,N-(2,5-二羟基苄基)-5-氨基水杨酸 |
CaMK; EGFR; Tyrosinase; Src | Angiogenesis; JAK/STAT signaling; Neuroscience; Proteases/Proteasome; Tyrosine Kinase/Adaptors |
lavendustin C (NSC 666251) 是 Ca2+钙调蛋白依赖性激酶 II 抑制剂,IC50为 0.2 µM。它抑制 EGFR 相关酪氨酸激酶和 pp60c-src(+)激酶,IC50分别为 0.012 和 0.5 µM。 | |||
T6028 |
PF 477736
PF 00477736,PF-477736,PF-736,PF-00477736,PF477736 |
c-Fms; VEGFR; FGFR; FLT; c-RET; Chk; CDK; Src; Aurora Kinase | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors |
PF 477736 (PF-736,PF-00477736) 是一种特异性、有效且具有 ATP 竞争性的 Chk1 抑制剂,Ki 值为0.49 nM。它也是Chk2抑制剂,Ki 值为 47 nM。它还抑制VEGFR2、Fms、Yes、Aurora-A、FGFR3、Flt3和Ret。 | |||
T8995 |
NCGC00262650
|
Others; Src | Angiogenesis; Others; Tyrosine Kinase/Adaptors |
NCGC00262650 是 AMA1-RON2 相互作用和 c-Src 酪氨酸激酶活性的抑制剂。 | |||
T9659 |
LCB 03-0110
3-(2-(3-(Morpholinomethyl)phenyl)thieno[3,2-b]pyridin-7-ylamino)phenol |
Discoidin Domain Receptor (DDR) | Tyrosine Kinase/Adaptors |
LCB 03-0110 (3-(2-(3-(Morpholinomethyl)phenyl)thieno[3,2-b]pyridin-7-ylamino)phenol) 是一种盘状结构域受体家族酪氨酸激酶的强效抑制剂,可强烈抑制多种酪氨酸激酶,包括 c-Src 家族、脾酪氨酸激酶、布鲁顿酪氨酸激酶和血管内皮生长因子受体 2,它们对免疫很重要细胞信号传导和炎症反应。 | |||
T8976 |
PD-089828
|
EGFR; FGFR; PDGFR; Src | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
PD-089828 是受体酪氨酸激酶 FGFR1、PDGFRβ 和 EGFR 的竞争性抑制剂,IC50分别为0.15、1.76 和 5.47 µM。它也是非受体酪氨酸激酶 c-Src 的非竞争性抑制剂,IC50 为 0.18 µM。 | |||
T32613 |
LCB 03-0110 dihydrochloride
|
Src | Angiogenesis; Tyrosine Kinase/Adaptors |
LCB 03-0110 Dihydrochloride 是BTK 和SYK 家族以及DDR2家族中c-Src 激酶(IC50=1.3 nM)和酪氨酸激酶的有效抑制剂。在体外抑制LPS 诱导的巨噬细胞活化和TGF-β1诱导的成纤维细胞活化,抑制巨噬细胞和成纤维细胞的活化,并抑制伤口愈合模型中的瘢痕形成。 | |||
T3211 |
Midostaurin
米哚妥林,N-Benzoylstaurosporine,PKC412,CGP41231,CGP 41251,苯甲酰基十字孢碱 |
Others; PKC | Chromatin/Epigenetic; Cytoskeletal Signaling; Others |
Midostaurin (PKC412) 是一种多靶点蛋白激酶抑制剂,有抗肿瘤活性,对 PKCα/β/γ、Syk、Flk-1、Akt、PKA、c-Kit、c-Fgr、c-Src、FLT3、PDFRβ和VEGFR1/2的IC50值范围为 22 到500 nM 之间。 | |||
T39178 |
Tyrosine Kinase Peptide 1
|
||
Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay. | |||
T83711 |
Abl Substrate Peptide TFA
|
||
Abl底物多肽是酪氨酸激酶Abl的多肽底物。在20 µM浓度下,相较于c-Src激酶,它被Abl选择性磷酸化。Abl底物多肽已被用于体外定量Abl激酶活性。 | |||
T71204 |
Apatinib HC
Rivoceranib HCl,YN-968D1 HCl |
||
Apatinib, also known as Rivoceranib and YN-968D1, is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. The free-base form is also known as Rivoceranib. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SR... | |||
T68581 |
AP23464
|
||
AP23464 is a potent adenosine 5'-triphosphate (ATP)-based inhibitor of Src and Abl kinases, displays antiproliferative activity against a human CML cell line and Bcr-Abl-transduced Ba/F3 cells (IC(50) = 14 nM. AP23464 ablates Bcr-Abl tyrosine phosphorylation, blocks cell cycle progression, and promotes apoptosis of Bcr-Abl-expressing cells. Biochemical assays with purified glutathione S transferase (GST)-Abl kinase domain confirmed that AP23464 directly inhibits Abl activity. Importantly, the lo... | |||
T37644 |
Bengamide B
|
||
Potent inhibitor of NF-κB activation (IC50 = 85 nM); decreases IκBα phosphorylation. Attenuates LPS-induced nitric oxide production and expression of TNF-α, IL-6 and MCP. Suppresses proliferation of HeLa and HCT116 cells. Anti-inflammatory and antitumor. Hu et al (2007) Regulation of c-Src nonreceptor tyrosine kinase activity by bengamide A through inhibition of methionine aminopeptidases. Chem.Biol. 14 764 PMID:17656313 |Johnson et al (2012) Myxobacteria versus sponge-derived alkaloids: the be... |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04384 |
Src Protein, Human, Recombinant (His & GST)
c-SRC,p60-Src,ASV,SRC1,S... |
Human | Baculovirus Insect Cells |
Src Protein, Human, Recombinant (His & GST) is expressed in Baculovirus insect cells with His and GST tag. The predicted molecular weight is 87.7 kDa and the accession number is P12931-1. | |||
TMPY-04383 |
CSK Protein, Human, Recombinant (GST)
c-src tyrosine kinase |
Human | Baculovirus Insect Cells |
CSK Protein, Human, Recombinant (GST) is expressed in Baculovirus insect cells with GST tag. The predicted molecular weight is 77 kDa and the accession number is P41240. | |||
TMPY-04760 |
CSK Protein, Mouse, Recombinant
c-src tyrosine kinase,AW... |
Mouse | Baculovirus Insect Cells |
CSK Protein, Mouse, Recombinant is expressed in Baculovirus insect cells. The predicted molecular weight is 50.9 kDa and the accession number is P41241. | |||
TMPY-04444 |
CSK Protein, Mouse, Recombinant (His & GST)
AW212630,p50CSK,c-src tyrosin... |
Mouse | Baculovirus Insect Cells |
CSK Protein, Mouse, Recombinant (His & GST) is expressed in Baculovirus insect cells with His and GST tag. The predicted molecular weight is 78.5 kDa and the accession number is P41241. | |||
TMPY-04411 |
YES1 Protein, Human, Recombinant (His & GST)
HsT441,c-yes,YES proto-oncogene 1, Src... |
Human | Baculovirus Insect Cells |
Proto-oncogene tyrosine-protein kinase Yes, also known as Proto-oncogene c-Yes, p61-Yes and YES1, is a cytoplasm protein that belongs to the protein kinase superfamily, Tyr protein kinase family and SRC subfamily. YES1 / c-Yes contains one protein kinase domain, one SH2 domain and one SH3 domain. It is thought that the subcellular distribution of Src-family tyrosine kinases, including c-Yes binding to the cellular membrane, is membranous and/or cytoplasmic. YES1 / c-Yes protein tyrosine kinase i... | |||
TMPK-00499 |
HGFR/c-Met Protein, Cynomolgus, Recombinant (His)
MET,oncogene MET,cMET,SF receptor... |
Cynomolgus | HEK293 Cells |
c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene.The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. HGFR/c-Met ... | |||
TMPK-00457 |
HGFR/c-Met Protein, Human, Recombinant (His & Avi)
cMET,Met (c-Met),MET,HGF/SF recep... |
Human | HEK293 Cells |
c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene.The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. HGFR/c-Met ... | |||
TMPK-00447 |
CD45 Protein, Human, Recombinant (aa 26-577, hFc)
CD45,CD45R,LCA,PTPRC,L-<... |
Human | HEK293 Cells |
PTPRC (also known as CD45),T cells require the protein tyrosine phosphatase CD45 to detect and respond to antigen because it activates the Src family kinase Lck, which phosphorylates the T cell antigen receptor (TCR) complex. CD45 ativates Lck by opposing the negative regulatory kinase Csk. Paradoxically, CD45 has also been implicated in suppressing TCR signaling by dephosphorylating the same signaling motifs within the TCR complex upon which Lck acts. CD45 Protein, Human, Recombinant (aa 26-577... | |||
TMPK-00423 |
CD45 Protein, Human, Recombinant (His & Avi)
CD45R,LY5,EC 3.1.3.48,B220,CD45,T... |
Human | HEK293 Cells |
PTPRC (also known as CD45),T cells require the protein tyrosine phosphatase CD45 to detect and respond to antigen because it activates the Src family kinase Lck, which phosphorylates the T cell antigen receptor (TCR) complex. CD45 ativates Lck by opposing the negative regulatory kinase Csk. Paradoxically, CD45 has also been implicated in suppressing TCR signaling by dephosphorylating the same signaling motifs within the TCR complex upon which Lck acts. CD45 Protein, Human, Recombinant (His & Avi... | |||
TMPK-00424 |
CD45 Protein, Human, Recombinant (His & Avi), Biotinylated
LCA,LY5,EC 3.1.3.48,CD45,L-C<... |
Human | HEK293 Cells |
PTPRC (also known as CD45),T cells require the protein tyrosine phosphatase CD45 to detect and respond to antigen because it activates the Src family kinase Lck, which phosphorylates the T cell antigen receptor (TCR) complex. CD45 ativates Lck by opposing the negative regulatory kinase Csk. Paradoxically, CD45 has also been implicated in suppressing TCR signaling by dephosphorylating the same signaling motifs within the TCR complex upon which Lck acts. CD45 Protein, Human, Recombinant (His & Avi... | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |